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Beta2.microglobulin kinetics in end-stage renal failure. The kinetics of
/32-microglobulin (f32m) were studied in five anephric or anuric hemodi-
alysis patients. Human l32m was isolated from peritoneal dialysate using
ion-exchange and gel chromatography and radiolabeled with 1251.
Patients were injected with 10 sCi labeled /32m. In one study (N = 4),
plasma activity was measured over 72 hours. In a second study (N = 4),
patients received low-flux dialysis 24 hours after injection and high-
clearance dialysis (BeIlco BL655) at 48 hours. Plasma activities were
fitted to a three-compartment, variable volume model. Endogenous f32m
levels (radioimmunoassay) were 56 6 mg/liter. The /32m distribution
volume was 12.7 2.0 liter (0.20 0.03 liter/kg) and the non-renal
clearance was 3.0 0.4 mI/mm. The generation rate, 9.9 1.7 mg/hr
(0.16 0.04 mglkg/hr), was similar to that measured in subjects with
normal renal function. The three compartment model derived from the
turnover data gave an adequate fit of the arterial concentrations of
endogenous and exogenous f32m during low-flux (nil 132m clearance) and
high-clearance (132m clearance of 19 mI/mm) dialysis. Simulations based
on this model indicate that extracorporeal treatment can at best remove
about 50% of weekly production. These results suggest that $2m
production is not increased in dialysis patients, that there is substantial
non-renal f32m clearance, and that the amount of f32m that can be
removed by extracorporeal therapy is therefore limited.
Dialysis-related amyloidosis is a common complication of
long-term dialysis. Consequences of amyloid deposition include
carpal tunnel syndrome, joint pathology, and bone destruction
through cyst formation [1—5]. A major component of this form
of amyloid is f32-microglobulin (/32m) [6, 7], and though other
species may be present as well [8, 9], attention has focused on
this 12,000 Dalton protein.
f32m is normally cleared by the kidneys at a rate comparable
to GFR [10, 11], then reabsorbed and catabolized in the tubules,
and serum levels are inversely related to GFR [121. Clearance
by conventional dialyzers is negligible as these membranes are
impermeable to /32m. Production of f32m in normals is 9 mg/
hr/70 kg [10]. Production may be increased in proliferative
disorders [13] and rheumatoid arthritis [14] as indicated by high
serum levels in the presence of normal renal function.
The etiology of dialysis amyloidosis and a strategy for pre-
venting it, or at least retarding its progression, remain elusive.
High serum /32m levels are an obvious precondition. There has
also been speculation that /32m generation is increased by
hemodialysis through contact with particular membranes, me-
chanical damage, or the fall in plasma osmolarity during dialysis
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[15—17]. The basis for these speculations is the observed rise in
serum 2m levels, to an extent greater than can be explained by
hemoconcentration, during dialysis with cellulosic membranes.
Others have argued that a proper correction of post-dialysis
levels should be based instead on the contraction of the
extracellular volume, in which case no anomalous increase in
f32m levels is seen [18, 19]. The /32m generation rate in dialysis
patients has not been measured.
One possible means of preventing amyloidosis is to lower
serum f32m levels through increased extracorporeal removal. A
measure of performance might be the fraction of weekly pro-
duction that is removed. High-flux dialysis, hemofiltration and
hemodiafiltration all remove measurable amounts of /32m and
can lower serum levels both acutely and in the longer term [15,
20—22], but at present there is no comprehensive model of /32m
kinetics in dialysis patients with which to evaluate these ther-
apies. The standard one-compartment model does not ade-
quately describe 2m kinetics during and between dialyses [23,
241, suggesting appreciable intravascular/extravascular resis-
tance to mass transfer. Two or more compartments are clearly
required. Another important unknown quantity is the non-renal
clearance of f32m in these patients. The larger this quantity, the
smaller the fraction of weekly production which can be re-
moved by a given extracorporeal therapy.
This study was undertaken to measure, in dialysis patients
without renal function, the 132m generation rate and extrarenal
clearance, and to develop a compartmental model for predicting
132m kinetics during dialysis.
Methods
Preparation of /32-microglobulin
Human /32m was isolated from peritoneal dialysate (HIV and
hepatitis B negative). Twenty liters of dialysate were concen-
trated 100-fold by ultrafiltration through a cuprophan dialyzer
(Asahi AM 710). The concentrate had a /32m concentration of
approximately 400 mg/mI. It was applied to a Sephacel DEAE
(Pharmacia Fine Chemicals, Uppsala, Sweden) column equili-
brated with 20 mrvt Tris HCI at pH 8.5 and eluted with a
discontinuous gradient of NaCI in the same buffer. Fractions
containing f32m were recovered at 250 to 300 mM NaC1. These
were reconcentrated by ultrafiltration (YM5 membrane, Ami-
con, Danvers, Massachusetts, USA), then further purified by
two passes on a Sephacryl S200 (Pharmacia) column (4.4 cm X
75 cm) eluted with phosphate buffered saline, pH 7.3 (PBS). Gel
filtration of the product showed a single peak at a position
equivalent to 12 kD and showed immunologic reactivity as
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Fig. 1. A. Chromogratogram of the injectate (1.0 X
30 cm column). B. Chromatograms of plasma
samples taken one hour (solid line, left scale, mean
of 4) and 24 hours (dashed line, right scale, mean of
5) after injection (1.0 x 25 cm column). Eluent flow
rate was 0.25 mI/mm, fractions were 1.0 ml.
assessed by radloimmunoassay. The purity of this product was
confirmed by isoelectric focusing and SDS-PAGE.
For each of the two studies performed, 2m was radio-
iodinated using a chloramine-T procedure. Approximately 6 mg
/32m in 2.6 ml PBS, pH 7.3 was reacted on ice with 800 Ci
Na1251 (Amersham, England, UK) and 60 1d chloramine-T
solution (2.5 mg/mi). After two minutes 60 tl of a solution of
sodium metabisuifite (2.5 mg/mi) and potassium iodide (5 mgI
ml) was added to stop the reaction. The entire solution was
loaded onto a Sephacryl S-200HR column (1.6 cm x 80 cm)
equilibrated with 1% pooled human serum albumin (Common-
wealth Serum Laboratories, Parkville, Victoria, Australia) in
sterile Duibecco's phosphate buffered saline, pH 7.3. Fractions
corresponding to the f32m protein peak were collected, pooled,
and sterilized by filtration (Millex GV 0.2 jim, Millipore,
Bedford, Massachusetts, USA) into sterile septum-sealed vials.
A portion of each vial was sampled for pyrogenicity and sterility
testing. The specific activity of the product was 20 CiImg
protein. A chromatogram of the injectate (Fig. lA) shows a
single protein peak and a small free iodide peak. SDS-PAGE of
the injectate (labeled /32m plus 1% human serum albumin) and
unlabeled 2m demonstrated low molecular weight bands that
co-migrated and corresponded with the main band in a com-
mercial human 2m preparation (Sigma Chemicals, St. Louis,
Missouri, USA).
Turnover studies
Two turnover studies were conducted. In the first, four
anephric hemodialysis patients were injected with 10 Ci la-
beled f32m on the morning after dialysis. Plasma was sampled at
5, 10, 15, and 30 minutes, 1, 2, 4, 6, 24, 48, and 72 hours. The
patients were not dialyzed during this period. In the second
study, four hemodialysis patients, including three of the first
group and an additional (anuric) patient, were injected with 10
Ci labeled 2m on the third day after their previous dialysis.
Plasma was sampled at 5, 10, 15, and 30 minutes, 1, 2, 4, and 24
hours. The patients received four hours of low-flux dialysis on
Table 1. Patient data
CAPD HD
Patient Age Sex years Diagnosis
1 57 M — 12.5 Chronic GN
2 65 F — 9 Staghorn calculi
3 53 F 4.6 1 Goodpasture's syndrome
4 64 M — 14.5 Chronic GN
a 34 M 3.5 1.5 Wegener's granulomatosis
Abbreviation chronic GN is chronic glomerulonephritis
a anuric
the second day and four hours of high-clearance dialysis on the
third (in one case, fourth) day.
All patients studied had been maintained on thrice weekly
hemodialysis for at least one year prior to the study, four with
cuprophan dialyzers and one with a cellulose acetate dialyzer.
The patients had been on dialysis, including CAPD, for 9 3
years. No patient displayed symptoms or signs of amyloidosis.
Patient details are given in Table 1.
Thyroid uptake of 125Jwas blocked by oral administration of
sodium iodide.
Dialysis studies
Four hour dialyses were performed using Gambro AK1O
machines and sterile dialysate produced by ultrafiltration
through a Belico BL655 high-flux dialyzer. Low-flux dialysis
was performed with Gambro cuprophan dialyzers (N = 3) and
one CDAK cellulose acetate dialyzer. High-clearance dialysis
was performed with Belico BL655 cellulose acetate dialyzers.
Blood flow was 200 mllmin and dialysate flow was 300 mllmin.
The mean weight loss during dialysis was 1.5 kg.
Arterial plasma was sampled from the cannula immediately
after cannulation, from the blood line at 5 minutes, 1, 2, 3 and
4 hours after the start of dialysis, and by venipuncture from the
fistula 30 minutes post-dialysis. Venous plasma was sampled at
(a)
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Fig. 2. The three compartment model of f32m distribution. K is the
total clearance, K12, K13 are intercompartmental clearance parameters
or permeability area products.
one hour (low-flux) or at I and 3 hours (high-clearance) for
clearance measurements. Dialysate was sampled at 5 minutes,
and 1, 2, 3 and 4 hours.
Analytical methods
Plasma and dialysate samples were counted (Packard Auto-
gamma 5650) intact and as supernatants of a 10% TCA (wt/vol,
final concentration) precipitation. Gel chromatography (Sepha-
cry! S200, 1.0 x 25 cm column) of plasma samples taken one
hour and 24 hours after injection showed no evidence of binding
of labeled f32m to plasma constituents (Fig. 1). Endogenous 2m
concentrations were measured by RIA (Pharmacia). Plasma
samples were diluted 1:20 before analysis. Dialysate samples
were assayed undiluted.
Modeling
The plasma disappearance curves of TCA-precipitable activ-
ity were fitted to the three compartment model in Figure 2. The
same model was used to simulate dialysis. The model assumes
endogenous input to, and elimination from, compartment one
only. Tracer input (bolus) was to compartment one (plasma)
and C1(t) was measured. Transfer between compartments and
to the environment are expressed in terms of clearances and
concentrations. In this formulation, the fluxes between com-
partments 1 and 2 are
and total elimination is
flux(l—2)= K12C1
flux (2—* 1) = K12C2
elimination = K01C1 = (Kr + Knr + Kd)CI
where Kr, Knr, and Kd are renal, non-renal and dialyzer
clearance, respectively. The material balance on compartment
1, with allowance for changing volume, is then
d(V1C1)Idt = V1dC1/dt + C1dV1/dt
=
—(K01 + K12 + K13)C1 + K12C2 + K13C3 + G
where G is the endogenous production rate. Material balances
on compartments 2 and 3 are derived similarly and, after
rearranging, the differential equations describing the compart-
mental concentrations become:
V1dC1Idt= —(K01+K12+K13+dV1/dt)C1+K12C2+K13C3+G
V2dC2/dt = K12C1 — (K12 + dV2/dt)C2
V3dC3/dt = K13C1 — (K13 + dV3/dt)C3
dV1/dt = 41 IdVd/dt
dV2/dt = 412dVd/dt
dV2/dt = 413dVd/dt
K01 = Kr + Knr + Kd
= Vi/IVi = V1/V
The distribution volume, d' is the sum of the compartmental
volumes. The following were assumed: the generation rate, all
clearances, and weight gain were constant; weight changes
were equivalent to changes in distribution (extracellular) vol-
ume; and the ratios of compartmental volumes to the distribu-
tion volume (41k) were constant.
The differential equations were solved numerically using a
fourth-order Runge-Kutta routine [25]. The parameters V1, V2,
V3, K12, K13, and K01 (= Knr, since Kr = Kd = 0) were
determined from the plasma disappearance curves by chi-
square (weighted least square) fitting using the Marquardt-
Levenberg method [25]. The variance of each data point was
calculated from the counting error and an assumed 1% coeffi-
cient of variation due to other sources of error; each data point
was then weighted by the inverse of the variance. The estimated
volumes refer to the time of injection. Superiority of three- over
two-compartment fits was assessed by analysis of variance [26].
The generation rate was calculated from the estimated clear-
ance and the mean serum /32m concentration over the study
period:
G = KnrCj(endogenous)
Dialyzer clearance was calculated from blood-side measure-
ments using:
Kd = (QIC — Q0C0)IC1
Q1 Qb(l — H)
Q0 = Qpi — Qf
and from dialysate-side measurements using:
= QdOCdO/CPI
where Qb and Qd are blood, plasma, and dialysate flow
rates, Q is the ultrafiltration rate, subscripts i and o denote inlet
and outlet, and H is the hematocrit.
Results are expressed as mean SD.
Results
TCA-precipitable and non-precipitable 125J activity are
shown for one patient (first study) in Figure 3. The rise in
non-precipitable activity, after the initial dilution, suggests
possible catabolism of the injected protein. The disappearance
curves of precipitable activity are plotted in Figures 4 and 5 for
the first and second studies, respectively.
K01 = Knr + Kr + Kd
912 Ode!! et al: f32m kinetics in renal failure
100
Time, hours
Fig. 3. Concentrations of TCA-precipitable (0) and non-precipitable
(0) activity, patient 2, first study.
The three-compartment model gave significantly better fits of
the 72-hour turnover data (first study) than did the two-com-
partment model (P < 0.001). Clearance was systematically
overestimated (7 2%) and distribution volume underesti-
mated (9 3%) by the two-compartment model. Since accurate
estimation of clearance and distribution volume require that the
tail of the disappearance curve be well-defined, in the second
study it was assumed that no f32m was removed during the
low-flux dialysis and the three-compartment model was fitted to
-the-data over--48-(or 72)hollrs. Pre-dialysis, but not intra- or
post-dialysis, data points were included in the fit and allowance
was made for the change in volume during the first dialysis.
The parameter estimates from the two studies are given in
Table 2. The clearance was 3.0 0.4 mi/mm, considerably less
than the 7.7 mi/mm measured in anephric sheep [27]. The
estimated plasma volume was 3.4 0.5 liter (53 9 ml/kg) and
the distribution volume was 12.7 2.0 liter (200 30 mllkg),
comparable to the expected plasma and extracellular volumes.
The f32m generation rate was 9.9 1.7 mg/hr (11.1 2.9
mg/hr/70 kg), similar to the generation rate measured in normals
by Karisson et al [10].
Under the assumption that free (non-precipitable) 125J activ-
ity might be indicative of catabolism of the /32m molecule, the
fractional conversion of protein-bound to free 125j was esti-
mated by performing a mass balance. The increase in free 125J
activity was compared to the decrease in bound 125! activity
over an interval when disequilibrium between compartments
was expected to be minimal. In the first study the chosen
interval was 24 to 72 hours; in the second, it was the interval
from 30 minutes post-dialysis (24 hours) to the start of the
following dialysis. The changes in concentration are plotted in
Figure 6. The total mass of labeled f32m at any time was
obtained from the three-compartment model, and the mass of
free label was calculated as the product of the plasma concen-
tration and an assumed distribution volume. The fractional
conversion was 37 13% if the distribution volume of free label
was assumed equal to that of f32m, and 65 26% if a volume
twice as large, comparable to the iodine space [28], was
assumed.
The dialysis results are summarized in Table 3. Dialyzer
clearances of labeled and endogenous /32m were similar
(Wilcoxon matched pairs test, P = 0.1) and clearances of both
species were nil with low flux dialysis. With high-clearance
dialysis, clearances measured on the blood side were higher
than those measured on the dialysate side. Two possible
explanations are uptake by the membrane and loss of f32m from
the dialysate samples to the tube walls. During low flux dialysis
endogenous fl2m levels rose 14 8% while labeled 2m levels
rose 1 4%. Levels of both solutes fell an average of 23%
during high-clearance dialysis.
Mean arterial concentrations of endogenous and labeled f32m
during dialysis are shown in Figure 7, along with the concen-
trations predicted from the three-compartment model, using the
individual patient parameters in Table 2 with appropriate ad-
justments to the volumes. A J32m clearance of 19 mllmin
(high-clearance) or zero (low-flux) was assumed. The agree-
ment between model and data indicates that volume changes
alone are sufficient to explain the rise in f32m concentration
during low flux dialysis and that the model has predictive
validity for low dialyzer clearances, at least. There is no
evidence that endogenous and exogenous /32m behaved differ-
ently.
The likely impact of therapies such as hemofiltration and
hemodialfiltration which can remove substantial amounts of
132m was assessed by simulation, under the assumption that
generation and non-renal clearance are independent of concen-
tration. Theoretical concentration profiles and removal rates
under different regimens were calculated using the mean param-
eter values in Table 2 and the following assumptions: three
tre-atments- -of -the- -same- -duration-spaed at 2, 2 and 3 day
intervals; constant rate of weight gain; and the same post-
dialysis weight for all dialyses. The initial 32m concentration
was set at 50 mg/liter and the model was run for three simulated
weeks. The results summarized in Figures 8 to 11 refer to the
third week, though concentrations stabilized by the second
week.
Concentration profiles during the midweek dialysis are shown
in Figure 8 for zero and 2 liter weight loss. For comparison,
profiles based on a one-pool model with the same total distri-
bution volume are also shown. Nonlinearity, seen even when
volume is held constant, and the post-dialysis rebound reflect
the substantial intravascular/extravascular barrier. Aside from
dialyzer clearance the important factors are the intrabody
clearances (compare the one and three-pool models) and weight
loss. Renal clearance up to 5 mi/mm and variations in genera-
tion rate had little effect on post/pre-ratios. Nor was there a
significant difference in post/pre-ratios between the first and
second weeks of the simulation.
Weekly profiles (with Kr = 0) are shown in Figure 9 for
clearances up to 80 mI/mm. With Kd = 0, concentrations rise
during dialysis and fall during the interval. The other profiles
have a more conventional shape, with concentration highest
after the long interval. In Figure 10, weekly removal as a
fraction of total f32m production is plotted against Kdtd/V for
several levels of residual renal function. While a six hour
procedure gives slightly greater removal, for the same Kdtd/V,
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than a four hour procedure, the difference is not large. This
suggests that Kdtd/V may be useful for quantifying the amount
of dialysis with respect to J32m. It is also apparent that inter-
mittent therapy can, at best, remove about 50 to 60% of
production, less if renal function is present. Comparison with
the one-pool model indicates that removal is limited primarily
because the therapy is intermittent and competing with the 3
mi/mm non-renal clearance, not because of intrabody mass
transfer resistance. Finally, midweek predialysis levels for
different levels of Kr are plotted against Kd in Figure 11. Again,
the influence of residual renal function is clear. The decrease in
pre-dialysis 2m levels to be expected with an increased Kd,
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Fig. 4. Concentrations of TCA-precipitab!e
activity, first study.
Fig. 5. Concentrations of TCA-precipitab!e
activity, second study. Low-flux dialysis at 24
hours, high-clearance dialysis at 48 (or 72)
hours.
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Table 2. Parameter estimates for three compartment model
Patient
Weight
kg
V1
liter
Knr
mI/mm
V2
liter
K12
mI/mm
V3
liter
K13
mI/mm
Vd
liter
Serum
f32m
mg/liter
G
mgi
hr
First study
1 76 3.1 2.6 3.2 75 6.1 26 12.4 58 9.0
2 53 2.8 2.9 1.7 57 6.3 31 10.8 63 10.8
3 58 3.9 3.5 3.8 93 6.0 22 13.6 52 11.0
4 66 3.9 2.7 2.7 77 6.6 28 13.3 56 9.0
Mean 63 3.4 2.9 2.8 75 6.3 27 12.5 57 10.0
SD 10 0.6 0.4 0.9 15 0.3 4 1.2 5 1.1
Second study
1 77 3.4 3.3 2.3 79 7.2 39 12.4 52 10.3
2 56 2.7 3.4 1.9 66 7.4 32 12.0 63 12.7
4 66 3.8 2.7 2.1 105 10.7 35 16.6 55 8.9
5 58 3.3 2.6 1.9 81 4.8 28 10.1 47 7.3
Mean 64 3.3 3.0 2.1 83 7.5 34 12.9 54 9.8
SD 10 0.4 0.4 0.2 16 2.4 5 2.7 7 2.3
Per kg, both studies
Mean 0.053 0.047 0.039 1.25 0.109 0.48 0.201 0.159
SD 0,009 0.010 0.011 0.25 0.027 0.09 0.032 0.041
>
0a
C
a
a
I)
0
C
both in absolute and relative terms, is strongly dependent on
Kr.
Discussion
Whereas a two-compartment model provides an adequate fit
to f32m kinetics when renal function is normal [10, 271, the
turnover data in this study were better fitted by three compart-
ments: a small, rapidly equilibrating compartment, presumably
representing the viscera with their more open capillary archi-
tecture, and a larger, more slowly equilibrating compartment,
both communicating with the plasma compartment. Chanard et
al [291 have also recently reported that three exponentials are
required to fit turnover data in dialysis patients. The parameter
estimates, except for the clearance, were similar to those
previously determined in anephric sheep [27]. The estimated
distribution volume, 20% of body weight, was similar to the
17% measured in normals [10] and the 18% estimated from fJ2m
kinetics during hemofiltration [19].
There was no evidence that /32m generation was increased in
these patients. Generation rates were similar to those deter-
mined in normals [10], perhaps slightly higher when adjusted for
body weight. The rise in f32m levels during low-flux dialysis was
adequately explained by contraction of the extracellular vol-
ume, as first suggested by Bergstrom and Wehie [18], and as
150
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Fig. 6. The increase in concentration of non-
precipitable 125j plotted against the decrease in
concentration of precipitable 125J, The increase and
500 decrease are relative to the concentrations at t 24
hr (30 minutes after low-flux dialysis in the second
study).
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Table 3. Clearances (mllmin) and post-dialysis/pre-dialysis
concentration ratios for labeled and endogenous /32m during
low-flux and high-clearance dialysis
Labeled
f32m
Endogenous
/32m
Low-flux
Clearance: blood side (N = 4) 2 5 —1 8
dialysate size (N = 20) 1 1 0 1
Cpost/Cpre (N = 4)
High-clearance
1.01 0.04 1.14 0.08
Clearance: blood side (N = 9) 17 8 22 4
dialysate side (N = 18) 2 5 —1 8
Cpost/Cpre (N = 4) 0.77 0.05 0.77 0.06
demonstrated by others using myoglobin [301 and inulin [19] as
extracellular volume markers. It is perhaps worth noting that
simulation showed that an assumed 100% increase in /32m
generation rate during dialysis would increase post-dialysis
levels an additional 10% only. It is clear then that the hypoth-
esis that amyloidosis results from enhanced f32m production is
not tenable.
A second hypothesis is that amyloidosis is simply a conse-
quence of prolonged exposure to elevated j32m levels and that
development of amyloidosis can be slowed only by reducing
those levels. The non-renal clearance of 3 mI/mm and the model
of 132m kinetics offer some guidance here. The non-renal clear-
ance is such that a small additional clearance, acting continu-
ously, can have a significant impact on f32m levels. Thus
Vincent et a! [31] showed that f32m levels in hemodialysis
patients increased markedly with time and that this increase
was largely explained by greater diuresis in short-term patients.
Similarly, Blumberg and Burgi [32] found a significant correla-
tion between the reciprocal of serum f32m and creatinine clear-
ance. In terms of our results, this relation can be written
1/C = (Knr + Kr)/G = (18 + 6Kr) X 10 3(liter/mg)
which fits their data reasonably well. Others have stressed the
importance, in comparative studies, of matching groups for
similar residual function [33]. Periodic measurement of renal
function in longitudinal studies would seem equally important.
CAPD also provides a small f32m clearance on the order of 0.7
to 1.0 mI/mm [32, 34, 35] and assuming Knr = 3 mllmin and no
renal function, one would expect /32m levels in CAPD patients
to be 75 to 80 percent of those in hemodialysis patients. Though
measured ratios range widely, from 60 to 100% [32, 36—38],
when concentrations were corrected for renal function the ratio
was approximately 75% [36, 37].
The simulations of intermittent therapy were based on a
compartmental model that was derived from turnover studies
conducted under conditions that approximated steady state and
was tested successfully against minor perturbations of 132m
levels. While extrapolation beyond these conditions entails
some uncertainty, the simulations provide at least a rough
perspective on the problem of manipulating f32m levels. Pre-
dicted concentration profiles during dialysis (or other proce-
dure) did not follow a single exponential decay, indicating the
inappropriateness of a one-pool model. This was seen in our
experimental results (Fig. 7), is evident in the concentration
profiles of Floege et a! [23] when replotted on a logarithmic
scale, and can also be inferred from the post-procedure rebound
reported by Canaud et al [24], which was interpreted by them as
extra generation of 2m. Volume changes, whether due to fluid
removal, as modeled here, or to fluid shifts between the
extracellular and intracellular spaces [19], which was not con-
sidered, also affect the concentration profiles. Residual renal
function and small changes in generation rate had negligible
effect.
Over the longer term, the simulations showed that concen-
trations stabilized one week alter beginning a new therapeutic
regimen, indicating that two to three weeks is sufficient time to
evaluate a procedure. The serial measurements of Blumberg
and Burgi [32] illustrate this well. The simulations also showed
that the reduction in predialysis /32m levels resulting from a
given clearance is smaller than might be expected, particularly
when renal function is present. Studies of high-removal tech-
niques have achieved reductions of 20 to 37% in predialysis f32m
levels [20—22, 32], but comparison with the model is not
possible in most cases because sufficient information, especially
clearances, was rarely given. Shinzato, Kobayakawa and
Maeda [21] reported a decrease in predialysis levels of 27% with
HDF using the Hospal AN69 HF with a clearance estimated to
be 35 ml!min under the conditions employed (Fig. 1 in their
paper). Adjusting for the different mean patient weight (50 kg)
and longer procedure (4.5 hr), the expected decrease according
to the model is 31% for mid-week pre-dialysis levels and 23%
for the first dialysis of the week, indicating rough agreement.
Finally, the inherent limitations of intermittent therapy are
clearly illustrated in Figure 10, which suggests that extracorpo-
real removal can account for, at best, about half of weekly 132m
production. Assuming amyloid deposition is proportional to
132m concentration, this would double the symptom-free inter-
val. The idea that hemofiltration or any other method can
remove total weekly /32m production [39] and thereby prevent
amyloidosis is fallacious.
Over a ten year period the average individual produces, and
disposes of, close to a kilogram of f32m. In the anephric patient
undergoing conventional dialysis, disposal routes are limited to
total or partial catabolism and deposition of the intact molecule
or fragment thereof as amyloid. The clearance measured in the
turnover studies represents the sum of these processes. Depo-
sition of '311-labeled 32m in joints a few days after injection has
been demonstrated [40] and 2m fragments have also been
identified in amyloid [8]. These several pathways cannot be
distinguished with certainty from the present data, but assum-
ing that J32m fragments constitute a minor fraction of amyloid,
that excretion and thyroid uptake of free 125J were negligible,
and that non-precipitable 125J was a catabolic product, the
estimated conversion of bound to free 125J activity suggests that
one-half or more of the injected protein may have been catab-
olized. Thus a third hypothesis regarding the pathogenesis of
amyloidosis is that some other factor in the presence of elevated
f32m levels favors deposition as amyloid over catabolism. Re-
duced proteolysis [41] and chronic subclinical inflammation [42]
have been suggested, as has aluminum exposure [43], although
the increased burden of chelatable aluminum in patients with
amyloidosis may be effect rather than cause. It could also be
that the cytokines previously thought to cause amyloidosis by
Fig. 7. Arterial concentrations of endogenous
(square) and labeled (circle) f32m during low-flux
(filled symbol) and high-clearance (open symbol)
dialysis. Lines represent model predictions.
Fig. 8. Concentration of 2m during and after dialysis
for extracorporeal clearances Kd = 0 to 80 mI/mm.
6 Weight = 64 kg. Three-pool model, weight loss = 2 kg
(solid lines) or zero (dashed lines). One-pool model,
weight loss = 2 kg (dotted lines).
increasing /32m production [151 do so by creating conditions
favoring amyloid formation [44].
Finally, it is conceivable that f32m itself is a pathogenetic
factor. There is accumulating evidence that /32m is not simply a
structural adjunct to the MHC class I molecule but has signif-
icant biological activity in its own right. It has been shown to
stimulate collegenase synthesis in synovial cells [45], to influ-
ence the activity of bone cells [46], and to have chemotactic
activity [47]. It is possible, then, that elevated /32m levels alone
can induce a pathology which results in amyloid deposition. If
this is so, reduction of f32m levels might have a greater thai
proportional effect of the rate of amyloid formation.
Appendix 1. Nomenclature
volume of compartment i
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renal clearance (volltime)
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Fig. 9. Weekly 2m concentration profile according to
the three-pool model with K, = 0, = 4 hr, weight =
64 kg, weight gain = 1 kg/day, Kd = 0 to 80 mI/mm.
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Fig. 10. Extracorporeal removal (% of production) of /32m versus
KdtIV for different levels of renal function. Weight = 64 kg. Three pool
Kt/vol
Fig. 11. Midweek predialysis f32m levels versus Kdtd/V and
0 to 5 mI/mm. Three-pool model, weight = 64 kg, td = 4 hr.
Kdfor K, =
model, td = 4 hr (solid lines); three pool model, td = 6 hr (dashed line);
one-pool model, td = 4 hr (dotted line). Upper scale gives Kd for td =
4 hr.
Qd clialysate flow rate, mllmin
Q, ultrafiltration rate, mllmin
C plasma concentration
Knr non-renal clearance ho (subscript) inlet/outlet or arterial/venous
Kd extracorporeal clearance H hematocrit
K1 clearance between compartments i and j,
(vol/time)
fraction of total distribution volume change Acknowledgment
assigned to compartment
Q plasma flow rate, mllmin The assistance of ENKA AG (Wuppertal, F.R.G.) isacknowledged. gratefully
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